STOCKS

RECOMMENDED BROKERS  
f
Comments Rating 4.69 (390 reviews)
f
Comments Rating 4.68 (387 reviews)
f
Comments Rating 4.7 (384 reviews)
Volatile stocks stabilise in anticipation of job reports

Gilead HIV Trial Success Boosts Shares by 8%

Quick Look: Breakthrough Trial: Gilead’s Phase 3 HIV prevention trial with Lenacapavir showed 100% efficacy. Market Impact: Shares rose 8%; Lenacapavir could exceed $1.7 billion in sales. Study Details: Included

Sending
User Review
0 (0 votes)